ATN-161 trifluoroacetate salt ATN-161 TFA salt|cas:904763-27-5|西域试剂

ATN-161 trifluoroacetate salt ATN-161 TFA salt,95.0%

产品编号：Bellancom-13535A| CAS NO：904763-27-5| 分子式：C₂₅H₃₆F₃N₉O₁₀S| 分子量：711.67

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-13535A	￥800.00	杭州北京（现货）
Bellancom-13535A	￥1100.00	杭州北京（现货）
Bellancom-13535A	￥1600.00	杭州北京（现货）
Bellancom-13535A	￥4800.00	杭州北京（现货）
Bellancom-13535A	￥7700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ATN-161 trifluoroacetate salt ATN-161 TFA salt

产品介绍

ATN-161 trifluoroacetate salt 是一种新型 integrin α5β1 拮抗剂，在肝转移模型小鼠模型中，抑制血管生成。

生物活性

ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.

体外研究

The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy (p<0.01). In addition, combination therapy leads to a significant increase of apoptotic (TUNEL-positive) tumor cells (p<0.03), whereas single-agent therapy does not increase in TUNEL-positive tumor cells. ATN-161 treatment leads to a significant reduction in EC number (21% decrease) after a 48 hr incubation time compared to control (p<0.03). ATN-161 inhibites VEGF-induced migration and capillary tube formation in hCECs, but did not inhibit proliferation. ATN-161 decreases the number of cells migrating in response to VEGF in a dose-dependent manner starting at 100 nM (P<0.001 vs. VEGF group).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

The preliminary experiments with α5β1-negative human colon cancer xenografts (HT29) show that treatment with ATN-161 significantly reduces tumor weight and vessel density. Injection of ATN-161 after laser photocoagulation inhibits choroidal neovascularization (CNV) leakage and neovascularization to an extent similar to AF564.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

H₂O : 5 mg/mL (7.03 mM; ultrasonic and warming and heat to 60°C)

DMSO : 1 mg/mL (1.41 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.4051 mL	7.0257 mL	14.0515 mL
5 mM	0.2810 mL	1.4051 mL	2.8103 mL
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶